About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Cancer Drug Fails in Trial

by Rathi Manohar on February 8, 2011 at 2:17 PM
Font : A-A+

 Cancer Drug Fails in Trial

Britain's second-biggest drug manufacturer, AstraZeneca withdrew the clinical trials of its prostate cancer drug, zibotentan, as the beneficial efficacy of the drug was proving to be questionable.

A Phase III study was cancelled when it was established that the drug was no better than standard therapy. †The Independent Data Monitoring Committee (IDMC) reviewed the matter and reported that there was no conclusive evidence that the drug would help patients with prostate tumors live longer or delay progression of the disease. When these primary targets - disease progression-free survival and overall survival - were not met, it was decided that it would be best to discontinue the trials.

Advertisement

Prostate cancer, the second most common cancer affecting men, especially in the West, poses the danger of developing into non-metastatic castrate-resistant prostate tumors (CRPC) when it does not respond to treatment.

†Zibotentan was expected to block the endothelin pathway that becomes uncontrolled with the advance of the disease, and thus slow down the spread of the cancer cells. †Unfortunately, the ENTHUSE (Endothelin A Use) clinical trial programme did not find this happening.
Advertisement

There is one more study that AstraZenta hopes to finish with successful results. The study will evaluate zibotentan plus chemotherapy rather than just chemotherapy alone, in men whose cancer had spread and who have been prescribed treatment with chemotherapy.

This is not the first disappointment AstraZenta faces in the trial studies of its drugs. It had to deal with failures in Recentin in colon cancer, Vandetanib for lung cancer, Motavizumab for respiratory problems in children, and Brilinta, a blood thinning drug for heart problems.

Although AstraZeneca has led the field in its innovative medicines, observers feel that the company has to be more thorough in its research strategies.



Source: Medindia
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
World Heart Day in 2022- Use Heart for Every Heart
Anemia among Indian Women and Children Remains a Cause of Concern- National Family Health Survey-5
H1N1 Influenza Prevention in Children: What Parents Need to Know
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Cancer and Homeopathy Signature Drug Toxicity Cancer Facts Cancer Tattoos A Body Art Oncology Drug Delivery Systems Common Lifestyle Habits that Cause Diseases Health Benefits of Dandelion Plant Immune Checkpoint Inhibitors for Cancer Treatment 

Most Popular on Medindia

Calculate Ideal Weight for Infants Loram (2 mg) (Lorazepam) The Essence of Yoga Drug Interaction Checker Indian Medical Journals Drug - Food Interactions Sinopril (2mg) (Lacidipine) How to Reduce School Bag Weight - Simple Tips Find a Doctor Selfie Addiction Calculator
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
×

Cancer Drug Fails in Trial Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests